Roche, Polyphor sign $548M deal to develop superbug antibiotic

11/4/2013 | Reuters

Roche Holding has signed a $548 million agreement with Polyphor for the development and commercialization of experimental antibiotic POL7080 to fight drug-resistant infections in hospitals. Under the deal, Roche will pay $38.4 million upfront. In addition, Polyphor is entitled to receive double-digit royalties on product sales.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN